Eton Pharmaceuticals entered into an Asset Purchase Agreement to acquire commercial assets of Wellstat Therapeutics Corporation and Wellstat Biologics Corporation for $37 million, and also amended the Asset Purchase Agreement with Azurity Pharmaceuticals to sell back royalty interests for $5.5 million.